Cardiovascular effects of antimuscarinic agents in overactive bladder

Expert Opinion on Drug Safety

Volumn 12, Issue 6, 2013, Pages 815-827

  Rosa, Gian Marco ^a   Bauckneht, Matteo ^a   Scala, Carolina ^a   Tafi, Emanuela ^a   Leone Roberti Maggiore, Umberto ^a   Ferrero, Simone ^a   Brunelli, Claudio ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Antimuscarinics; Cardiovascular adverse effects; Drug drug interactions; Heart rate; QT prolongation

Indexed keywords

DARIFENACIN; DICYCLOVERINE; FESOTERODINE; IMIDAFENACIN; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PROPIVERINE; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE;

CARDIOVASCULAR EFFECT; CLINICAL TRIAL; COMORBIDITY; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY MONITORING; HEART FUNCTION; HEART RATE VARIABILITY; HIGH RISK POPULATION; HUMAN; OVERACTIVE BLADDER; PERIPHERAL EDEMA; QT PROLONGATION; REVIEW; SUDDEN CARDIAC DEATH; TACHYCARDIA; TORSADE DES POINTES;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANIMALS; CARDIOVASCULAR DISEASES; DRUG INTERACTIONS; DRUG MONITORING; HEART RATE; HUMANS; MUSCARINIC ANTAGONISTS; RISK FACTORS; URINARY BLADDER, OVERACTIVE;

EID: 84886609744     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2013.813016     Document Type: Review

References (110)

1. Haylen BT, de Ridder D, Freeman RM, et al. International Urogynecological Association; International Continence Society. An International Urogynecological Association (IUGA)/ International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 2010;29:4-20
2. Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 2010;21:5-26
3. Stewart WF, Corey R, Herzog AR, et al. Prevalence of overactive bladder in women: Results from the NOBLE program. Int Urogynecol J 2001;12:S66
4. Coyne KS, Sexton CC, Irwin DE, et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: Results from the EPIC study. BJU Int 2008;101:1388-95
5. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study. Eur Urol 2006;50:1306-14
6. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-36
7. Coyne KS, Sexton CC, Bell JA, et al. The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: Results from OAB-POLL. Neurourol Urodyn 2012; Epub ahead of print
8. Cardozo L. Systematic review of overactive bladder therapy in females. Can Urol Assoc J 2011;5:S139-42
9. Abrams P, Andersson KE, Buccafusco JJ, et al. Muscarinic receptors: Their distribution and function in body sistems, and the implications for treating overactive bladder. Br J Pharmacol 2006;148:565-78
10. Matsui M, Motomura D, Karasawa H, et al. Multiple funcional defects in peripheral autonomic organs in mice lacking muscarinic acetylcoline receptor gene for the M3 subtype. Proc Natl Acad Sci USA 2000;97:9579-84
11. Hedge SS, Eglen RM. Muscarinic receptor subtypes modulating sooth miscle contractility in the urinary bladder. Life Sci 1999;64:419-28
12. Chess-Williams R. Muscarinic receptors of the urinary bladder: Detrusor, urothelial and prejunctional. Auton Autacoid Pharmacol 2002;22:133-45
13. Leone Roberti Maggiore U, Salvatore S, Alessandri A, et al. Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females. Expert Opin Drug Metab Toxicol 2012;8:1387-408
14. Orefelein MG. Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder. Drug Saf 2011;34:733-54
15. Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int 2007;100:987-1006
16. Harrington AM, Peck CJ, Liu L, et al. Localization of muscarinic receptors M1R, M2R and M3R in the human colon. Neurogastroenterol Motil 2010;22:999-1008
17. Ishizaka N, Noda M, Yokoyama S, et al. Muscarinic acetylcholine receptor subtypes in the human iris. Brain Res 1998;787:344-7
18. Dmochowski RR, Sand PK, Zinner NR, Staskin DR. Trospium 60 mg once daily (QD) for overactive bladder syndrome: Results from a placebo-controlled interventional study. Urology 2008;71:449-54
19. Chancellor M, Boone T. Anticholinergics for overactive bladder therapy: Central nerous system effects. CNS Neurosci Ther 2012;18:167-74
20. Asche CV, Kim J, Kulkarni AS, et al. Presence of central nervous system, cardiovascular and overall co-morbility burden in patients with overactive bladder disorder in a real-word setting. BJU Int 2011;109:572-80
21. Andersson KE, Sarawate C, Kahler KH, et al. Cardiovascular morbility, heart rates and use of antimuscarinics in patients with overactive bladder. BJU Int 2010;106:268-74
22. Harvey RD. Muscarinic receptor agonists and antagonists: Effect on cardiovascular function. In: Fryer AD, Christopoulos A, Nathanson NM, editors. Muscarinic receptors, handbook of experimental pharmacology. Springer-Verlang; Berlin Heidelberg: 2012. p. 299-316
23. Andersson KE, Campeau L, Olshansky B. Cardiac effects of muscarinic receptor antagonists used for voiding disfunction. Br J Clin Pharmacol 2011;72:186-96
24. Stengel PW, Gomeza J, Wess J, et al. M (2) and M(4) receptor knockout mice: Muscarinic receptor function in cardiac and smooth muscle in vitro. J Pharmacol Exp Ther 2000;292:877-85
25. Dhein S, Van Koppen CJ, Brodde OE. Muscarinic receptors in the mammalian heart. Pharmacol Res 2001;44:161-82
26. Abramochkin DV, Suris MA, Borodinova AA, et al. M3 cholinoreceptors: New mediator of acetylcholine action on myocardium. Neurochem J 2008;2:90-4
27. Wang H, Shi H, Lu Y, et al. Pilocarpine modulates the cellular electrical properties of mammalian hearts by activating a cardiac M3 receptor and a K + current. Br J Pharmacol 1999;126:1725-34
28. Abramochkin DV, Tapilina SV, Sukhova GS, et al. Functional M3 cholinoreceptors are present in pacemaker and working myocardium of murine heart. Eur J Physiol 2012;463:523-9
29. Wang Z, Shi H, Wang H. Functional M3 muscarinic acetylcholine receptors in mammalian hearts. Br J Pharmacol 2004;142:395-408
30. Cook S, Togni M, Schaub MC, et al. High heart rate: A cardiovascular risk factor? Eur Heart J 2006;27:2387-93
31. Majercak I. The use of heart rate variability in cardiology. Bratisl Lek Listy 2002;103:368-77
32. Gutman GA, Chandy KG, Grissner S, et al. International union of pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacol Rev 2005;57:473-508
33. Witchel HJ. Drug-induced hERG block and long QT syndrome. Cardiovasc Ther 2011;29:251-9
34. Schlotthauer K, Bers DM. Sarcoplasmic reticulum Ca2+ release causes myocyte depolarization-underlying mechanism and threshold for triggered action potentials. Circ Res 2000;87:774-80
35. Makkar RR, Fromm BS, Steinman RT, et al. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993;270(21):2590-7
36. Liu XK, Wang W, Ebert SN, et al. Female gender is a risk factor for torsades de pointes in an in vitro animal model. J Cardiovasc Pharmacol 1999;34(2):287-94
37. Shuba YM, Degtiar VE, Osipenko VN, et al. Testosterone-mediated modulation of HERG blockade by proarrhythmic agents. Biochem Pharmacol 2001;62(1):41-9
38. Liu XK, Katchman A, Whitfield BH, et al. In vivo androgen treatment shortens the QT interval and increases the densities of inward and delayed rectifier potassium currents in orchiectomized male rabbits. Cardiovasc Res 2003;57(1):28-36
39. Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995;50(2):222-39
40. Mao J, Scherlag BJ, Liu Y, et al. The atrial neural network as a substrate for atrial fibrillation. J Interv Card Electrophysiol 2012;35:3-9
41. Yamada S, Maruyama S, Takagi Y, et al. In vivo demonstration of M3 muscarinic receptor subtype selectivity of darifenacin in mice. Life Sci 2006;80:127-32
42. Chapple C, Steers W, Norton P, et al. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int 2005;95:993-1001
43. Green L, Kerney D. Patient experience with darifenacin - results of a short-term community- based survey in managing overactive bladder. Curr Med Res Opin 2011;27:431-7
44. Kay GG, Wesnes KA. Pharmacodynamic effects of darifenacin, a muscarinic M selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers. BJU Int 2005;96:1055-62
45. Nichols D, Colli E, Goka J, et al. Darifenacin demonstrated no adverse effect on cognitive and cardiac functions: Results from a double-blind, rabdomized, placebo-controlled study [abstract]. Neurourol Urodyn 2006;20:354
46. Olshansky B, Ebinger U, Brum J, et al. Differential pharmacological effects of antimuscarinic drugs on heart rate: A randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants ‡ 50 years. J Cardiovasc Pharmacol Ther 2008;13:241-51
47. Serra DB, Affrime MB, Bedigian MP, et al. QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder. J Clin Pharmacol 2005;45:1038-47
48. Kraus SR, Ruiz-Cerdá JL, Martire D, et al. Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder. Urology 2010;76:1350-7
49. Malhotra BK, Wood N, Sachse R. Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine. Int J Clin Pharmacol Ther 2009;47:570-8
50. Kelleher CJ, Tubaro A, Wang JT, et al. Impact of fesoterodine on quality of life: Pooled data from two randomized trials. BJU Int 2008;102:56-61
51. Van Kerrebroeck PEV, Heesakkers J, Berriman S, et al. Long-term safety, tolerability and efficacy of fesoterodine treatment in subjects with overactive bladder symptoms. Int J Clin Pract 2010;64:584-93
52. Nitti VW, Dmochowski R, Sand PK, et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol 2007;178:2488-94
53. Chapple C, Van Kerrebroeck PEV, Tubaro A, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 2007;52:1204-12
54. Toviaz- (fesoterodine fumarate). US prescribing information. Pfizer, Inc; New York: 2012
55. Malhotra B, Wood N, Sachse R, et al. Thorough QT study of the effect of fesoterodine on cardiac repolarization. Int J Clin Pharmacol Ther 2010;48:309-18
56. Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119:8s-21s
57. Malhotra B, Alvey C, Gong J, et al. Effects of fesoterodine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. Br J Clin Pharmacol 2011;72:257-62
58. Kobayashi F, Yageta Y, Segawa M, et al. Effects of imidafenacin (KRP-197/ONO- 8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. High affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland. Arzneimittelforschung 2007;57:92-100
59. Nishijima S, Sugaya K, Kadekawa K, et al. Comparison of the effect of antimuscarinic agents on bladder activity, urinary ATP level and autonomic nervous system in rats. Biomed Res 2009;30:107-12
60. Homma Y, Yamaguchi O. A randomized, double-blind, placeboand propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. Int J Urol 2009;16:499-506
61. Hasegawa C, Ohno T, Nakade S, et al. population pharmacokinetics and exposure-response relationship of a muscarinic receptor antagonist, imidafenacin. Drug Metab Pharmacokinet 2012; Epub ahead of print
62. Nakade S, Ohno T, Nakayama K, et al. No Effect of Imidafenacin, a Novel Antimuscarinic Drug, on Digoxin Pharmacokinetics in Healthy Subjects. Drug Metab Pharmacokinet 2008;23:95-100
63. Jirschele K, Sand PK. Oxybutynin: Past, present, and future. Int Urogynecol J 2012; Epub ahead of print
64. Baigrie RJ, Kelleher JP, Fawcett DP, et al. Oxybutynin: Is it safe? Br J Urol 1988;62:319-22
65. Ditropan- (Oxybitynin Chloride) tablets and syrup. US prescribing information. Ortho-McNeil Pharmaceutical, Inc; Raritan (NJ): 2008 Ditropan XL- (Oxybutynin Chloride
66. extended release tablets. US prescribing informations. Ortho-McNeil-Janssen Pharmaceuticals, Inc; Raritan (NJ): 2009
67. Abrams P, Cardozo L, Chapple C, et al. 1032 study group. Comparison of the efficacy, safety and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome. Int J Urol 2006;13:692-8
68. Chapple CR, Abrams P. Comparison of darifenacin and oxybutynin in patients with overactive bladder: Assessment of ambulatory urodynamics and impact on salivary flow. Eur Urol 2005;48:102-9
69. Hussain RM, Hartigan-Go K, Thomas SH, Ford GA. Effect of oxybutynin on the QT interval in elderly patients with urinary incontinence. Br J Clin Pharmacol 1996;41:73-5
70. Jones SE, Shuba LM, Zhabyeyev P, et al. Differencies in the effects of urinary incontinence agents S-oxybutynin and terodiline on cardiac K+ currents and action potentials. Br J Pharmacol 2000;131:245-54
71. Jones SE, Kasamaki Y, Shuba LM, et al. Analysis of the electrophysiologic effects of short-term oxybutynin on guinea pig and rabbit ventricular cells. J Cardiovasc Pharmacol 2000;35:334-40
72. Andersson KE, Chapple CR, Cardozo L, et al. Pharmacological treatment of urinary incontinence. ICS guidelines 2009. 4th International Consultation on Incontinence. Curr Opin Urol 2009;19:380-94
73. Haruno A. Inhibitory effects of propiverine hydrochloride on the agonist-induced or spontaneous contractions of various isolated muscle preparations. Arzneimittelforschung 1992;42:815
74. Uchida S, Kurosawa S, Fujino Oki T, et al. Binding activities by propiverine and its N-oxide metabolites of L-type calcium channel antagonist receptors in the rat bladder and brain. Life Sci 2007;80:2454-60
75. Dorschner W, Stolzenburg JU, Griebenow R, et al. Efficacy and cardiac safety of propiverine in elderly patients - a double-blind, placebo-controlled clinical study. Eur Urol 2000;37:702-8
76. Dorschner W, Stolzenburg JU, Griebenow R, et al. The elderly patient with urge incontinence or urge-stress incontinence - efficacy and cardiac safety of propiverine. Aktuelle Urol 2003;34:102-8
77. Wuest M, Christ T, Hiller N, et al. Effects of three metabolites of propiverine on voltage-dependent L-type calcium currents in human atrial myocytes. Eur J Pharmacol 2008;598:94-7
78. Christ T, Wettwer E, Wuest M, et al. Electrophysiological profile of propiverine - relationship to cardiac risk. Naunyn-Schmiedeberg's Arch Pharmacol 2008;376:431-40
79. Donath F, Braeter M, Feustel C. The influence of propiverine hydrochloride on cardiac repolarization in healthy women and cardiac male patients. Int J Clin Pharmacol Ther 2011;49:353-65
80. Ohtake A, Ukai M, Hatanaka T, et al. In vitro ed in vivo tissue selectivity profile of solifenacin succinate (YM905 for urinary bladder over salivary gland in rats. Eur J Pharmacol 2004;492:243-50
81. Ikeda F, Kobayashi S, Suzuki M, et al. M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedeberg's Arch Pharmacol 2002;366:97-103
82. Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of Solifenacin succinate and extended release Tolderodine at treating overactive bladder syndrome: Results of the STAR Trial. Eur Urol 2005;48:464-70
83. Choo MS, Lee JZ, Lee JB, et al. Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: A randomized, prospective, double-blind multicentre study. Int J Clin Pract 2008;62:1675-883
84. Oreskovic S, But I, Banovic M, Goldstjn MS. The efficacy and safety of solifenacin in patients with overactive bladder syndrome. Coll Antropol 2012;36:243-8
85. Luo D, Liu L, Han P, et al. Solifenacin for overactive bladder: A systematic review and meta-analysis. Int Urogynecol J 2012;23:983-91
86. Smulders RA, Krauwinkel WJ, Swart PJ, Huang M. Pharmacokinetics and safety of solifenacin succinate in healthy young men. J Clin Pharmacol 2004;44:1023-33
87. Michel MC, Wetterauer U, Vogel M, de la Rosette JJ. Cardiovascular safety and overall tolerability of solifenacin in routine clinical use: A 12 week, open-label, post-marketing surveillance study. Drug Saf 2008;31:505-14
88. Asajima H, Sekiguchi Y, Matsushima S, et al. QT prolongation and torsades des pointes associated with Solifenacin in an 81-year-old woman. Br J Clin Pharmacol 2008;66:896-7
89. Hoffstetter S, Che Leong F. Solifenacin succinate for the treatment of overactive bladder. Expert Opin Drug Metabol Toxicol 2009;5:345-50
90. Clemett D, Jarvis B. Tolterodine: A review of its use in the treatment of overactive bladder. Drugs Aging 2001;41:298-304
91. Rentzhog L, Stanton SL, Cardozo L, et al. Efficacy and safety of tolterodine in patients with detrusor instability: A doseranging study. Br J Urol 1998;81:42-8
92. Nilvebrant L, Andersson KE, Gillberg PG, et al. Tolterodine a new bladder-selective antimuscarinic agent. Eur J Pharmacol 1997;327:195-207
93. Olshansky B, Foote J, Arguinzoniz M, et al. The effects of darifenacin and tolterodine on heart rate (HR) in patients with overactive bladder (OAB) [abstract 124]. Annual Meeting of the 92. International Continence Society; Christchurch, New Zealand. 2006. Available from: Https://www. icsoffice.org/publications/2006/pdf/0124 pdf 94.
94. pdf 94. Schiffers M, Sauermann P, Schurch B, et al. The effect of tolterodine 4 and 8 mg on the heart rate variability in healthy subjects. World J Urol 2010;28:651-6
95. Pfizer Detrol- (tolterodine tartrate tablets) US prescribing information March, 2008. Available from: Http:// media.pfizer.com/files/products/ uspi-detrol.pdf
96. Hsiao SM, Chang TC, Wu WY, et al. Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome. J Obstet Gynaecol Res 2011;37:1084-91
97. Kang J, Chen XL, Wang H, et al. Cardiac Ion Channel Effects of Tolterodine. JPET 2004;308:935-40
98. Malhotra BK, Glue P, Sweeney K, et al. Thorough QT study with recommended and supratherapeutic doses of tolterodine. Clin Pharmacol Ther 2007;81:377-85
99. Schwantes U, Topfmeier P. Importance of pharmacological and physicochemical properties for tolerance of antimuscarinic drugs in the treatment of detrusor instability and detrusor hyperreflexia-chances for improvement of therapy. Int J Clin Pharmacol Ther 1999;37:209-18
100. Halaska M, Ralph G, Wiedemann A, et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 2003;20:392-9
101. Pietzko A, Dimpfel W, Schwantes U, Topfmeier P. Influences of trospium chloride and oxybutynine on quantitative EEG in healthy volunteers. Eur Clin Pharmacol 1994;47:337-43
102. Beckmann-Knopp S, Rietbrock S, Weyhenmeyer R, et al. Inhibitory effects of trospium chloride on cytochrome P450 in human liver microsomes. Pharmacol Toxicol 1999;85:299-304
103. Rovner ES. Trospium chloride in the management of overactive bladder. Drugs 2004;64:2433-46
104. Sanctura XR- (trospium chloride extended release). US prescribing information. Allergan, Inc; Irvine (CA): 2008
105. Guay DR. Trospium chloride: An update on a quaternary anticholinergic for treatment of urge urinary incontinence. Ther Cli Risk Manag 2005;1:157-67
106. Dmochowski R, Staskin D. The Q-T interval and antimuscarinic drugs. Curr Urol Rep 2005;6:405-9
107. Drici MD, Clément N. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. Drug Saf 2001;24:575-85
108. Colucci VJ, Rivey MP. Tolterodine-warfarin drug interaction. Ann Pharmacother 1999;33:1173-6
109. Taylor Jr. Probable interaction between tolterodine and warfarin. Pharmacotherapy 2006;26:719-21
110. Glavind K, Chancellor M. Antimuscarinics for the treatment of overactive bladder: Understanding the role of muscarinic subtype selectivity. Int Urogynecol J 2011;22:907-17